Friday 31 January
Please note that this is the preliminary programma; times and titles are still subject to change
07.00 – 08.00 | Breakfast meeting for ECRs (NextGen DLB)
08.30 - 09.00 | Plenary V - Brain first vs body first in LBD
Per Borghammer (Aarhus, Denmark)
Chairs: Kejal Kantarci (Rochester, USA) & John O'Brien (Cambridge, UK)
09.00 - 09.30 | Plenary VI - Drug trials and novel targets in DLB
Dag Aarsland (Stavanger, Norway)
Chairs: Kejal Kantarci (Rochester, USA) & John O'Brien (Cambridge, UK)
09.30-10.00 | Rising Star Awards
Evelien Lemstra (Amsterdam, NL) & Simon Lewis (Sydney, Australia)
10.00 - 10.30 | COFFEE BREAK
10.30 - 12.00 | Symposium VII - Outcome measures in LBD
Chairs: Joe Kane (Dublin, Ireland) & Tanis Ferman (Boston, USA)
Oral presentations
- The utility of composite endpoints for tracking disease progression in Lewy body dementia, Elie Matar (Sydney, Australia)
- A standardised approach to outcome measurement in dementia with Lewy bodies: Core Outcome Set (COS) development, Iracema Leroi (Dublin, Ireland)
- LBD Caregiver Preferences for Peer-to-Peer Support in the Connect2Caregiver Research Study Cohort, Leah Forsberg (Rochester, USA)
- Comparing the diagnostic accuracy of different cognitive fluctuations scales for discriminating between Dementia with Lewy Bodies and Alzheimer's Disease, Miguel Tábuas-Pereira (Coimbra, Portugal)
- An update on the Lewy Body Dementia Domain rating scale (LBD-DRS), Joseph Kane (Dublin, Ireland)
12.00 - 13.00 | LUNCH / Poster session
13.00 - 14.15 | Symposium VIII - Therapy
Chairs: Alan Thomas (Newcastle, UK) & James Galvin (Boca Raton, USA)
Oral presentations
- What matters most? Exploring the treatment preferences of people with dementia with Lewy bodies and their care partners: a stated preference study, Paula Sinead (Dublin, Ireland)
- tACS and its Influence on Cognitive Performance and Alpha Oscillations in Dementia with Lewy Bodies, Laura Bonanni (Chieti, Italy)
- Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB), Lawrence Honig (New York, USA)
- Cognitive and behavioral outcomes in patients with dementia with Lewy bodies treated with nilotinib, Charbel Moussa (Washington, USA)
- Results from COG1201: A Proof-of-Concept Study of CT1812 in Participants with Mild-to-Moderate Dementia with Lewy Bodies, James Galvin (Boca Raton, USA)
14.15 - 14.30 | SHORT BREAK
14.30 - 15.15 | Debate: This house believes that DLB and PDD are still useful concepts
Moderator: John O'Brien (Cambridge, UK)
Supporting the motion: Simon Lewis (Sydney, Australia)
Opposing the motion: Dan Weintraub (Pennsylvania, USA)
15.15 - 15.30 | Closing